SPRUCE BIOSCIENCES INC (SPRB) Stock Fundamental Analysis

NASDAQ:SPRB • US85209E2081

82.96 USD
+0.27 (+0.33%)
Last: Feb 12, 2026, 08:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

SPRB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. SPRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SPRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SPRB has reported negative net income.
  • In the past year SPRB has reported a negative cash flow from operations.
  • In the past 5 years SPRB always reported negative net income.
  • In the past 5 years SPRB always reported negative operating cash flow.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • SPRB has a worse Return On Assets (-312.67%) than 91.78% of its industry peers.
  • SPRB has a worse Return On Equity (-888.95%) than 78.20% of its industry peers.
Industry RankSector Rank
ROA -312.67%
ROE -888.95%
ROIC N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SPRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SPRB has more shares outstanding
  • SPRB has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SPRB is higher compared to a year ago.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • SPRB has an Altman-Z score of -29.98. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
  • SPRB has a worse Altman-Z score (-29.98) than 87.38% of its industry peers.
  • There is no outstanding debt for SPRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.98
ROIC/WACCN/A
WACC12.43%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.54 indicates that SPRB should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.54, SPRB is doing worse than 80.11% of the companies in the same industry.
  • A Quick Ratio of 1.54 indicates that SPRB should not have too much problems paying its short term obligations.
  • The Quick ratio of SPRB (1.54) is worse than 78.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • SPRB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.06%.
  • Looking at the last year, SPRB shows a very negative growth in Revenue. The Revenue has decreased by -90.18% in the last year.
EPS 1Y (TTM)-19.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.43%
Revenue 1Y (TTM)-90.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • SPRB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.85% yearly.
  • SPRB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y77.01%
EPS Next 2Y32.64%
EPS Next 3Y18.41%
EPS Next 5Y14.85%
Revenue Next Year-100%
Revenue Next 2Y2.97%
Revenue Next 3Y25.64%
Revenue Next 5Y-14.87%

3.3 Evolution

SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2026 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SPRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SPRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SPRB's earnings are expected to grow with 18.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.64%
EPS Next 3Y18.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SPRB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (2/12/2026, 8:16:37 PM)

82.96

+0.27 (+0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)04-13
Inst Owners41.05%
Inst Owner Change0.78%
Ins Owners8.68%
Ins Owner Change0.22%
Market Cap88.77M
Revenue(TTM)697.00K
Net Income(TTM)-47.88M
Analysts80
Price Target235.11 (183.4%)
Short Float %6.24%
Short Ratio0.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)39.74%
Min EPS beat(2)-2.58%
Max EPS beat(2)82.06%
EPS beat(4)1
Avg EPS beat(4)-33.2%
Min EPS beat(4)-166.11%
Max EPS beat(4)82.06%
EPS beat(8)5
Avg EPS beat(8)-5.32%
EPS beat(12)8
Avg EPS beat(12)-0.08%
EPS beat(16)11
Avg EPS beat(16)2.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.02%
PT rev (3m)3576.24%
EPS NQ rev (1m)-21.8%
EPS NQ rev (3m)-130.22%
EPS NY rev (1m)-62.38%
EPS NY rev (3m)1.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 127.36
P/FCF N/A
P/OCF N/A
P/B 16.48
P/tB 16.48
EV/EBITDA N/A
EPS(TTM)-84.83
EYN/A
EPS(NY)-23.11
Fwd EYN/A
FCF(TTM)-44.44
FCFYN/A
OCF(TTM)-44.44
OCFYN/A
SpS0.65
BVpS5.03
TBVpS5.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -312.67%
ROE -888.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z -29.98
F-Score2
WACC12.43%
ROIC/WACCN/A
Cap/Depr(3y)8.1%
Cap/Depr(5y)65.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.43%
EPS Next Y77.01%
EPS Next 2Y32.64%
EPS Next 3Y18.41%
EPS Next 5Y14.85%
Revenue 1Y (TTM)-90.18%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y2.97%
Revenue Next 3Y25.64%
Revenue Next 5Y-14.87%
EBIT growth 1Y-14.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.67%
OCF growth 3YN/A
OCF growth 5YN/A

SPRUCE BIOSCIENCES INC / SPRB FAQ

Can you provide the ChartMill fundamental rating for SPRUCE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 1 / 10 to SPRB.


Can you provide the valuation status for SPRUCE BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to SPRUCE BIOSCIENCES INC (SPRB). This can be considered as Overvalued.


What is the profitability of SPRB stock?

SPRUCE BIOSCIENCES INC (SPRB) has a profitability rating of 0 / 10.


What is the financial health of SPRUCE BIOSCIENCES INC (SPRB) stock?

The financial health rating of SPRUCE BIOSCIENCES INC (SPRB) is 4 / 10.


What is the earnings growth outlook for SPRUCE BIOSCIENCES INC?

The Earnings per Share (EPS) of SPRUCE BIOSCIENCES INC (SPRB) is expected to grow by 77.01% in the next year.